Alder Biopharmaceuticals Inc (ALDR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9782
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alder’s clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The company’s eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.

Alder Biopharmaceuticals Inc (ALDR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Alder Biopharma Raises US$38 Million In Series D Financing 11
Licensing Agreements 13
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Equity Offering 15
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Debt Offering 26
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc – Key Competitors 28
Alder Biopharmaceuticals Inc – Key Employees 29
Alder Biopharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31
Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32
May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33
Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34
Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36
Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37
Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39
Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41
Corporate Communications 43
Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43
Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44
Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45
Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46
Product News 47
03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47
Clinical Trials 48
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48
Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49
Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharma Raises US$38 Million In Series D Financing 11
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc, Key Competitors 28
Alder Biopharmaceuticals Inc, Key Employees 29
Alder Biopharmaceuticals Inc, Subsidiaries 30

List of Figures
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Alder Biopharmaceuticals Inc (ALDR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • President Chain Store Corporation:戦略・SWOT・企業財務分析
    President Chain Store Corporation - Strategy, SWOT and Corporate Finance Report Summary President Chain Store Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Immunicum AB (IMMU):製薬・医療:M&Aディール及び事業提携情報
    Summary Immunicum AB (Immunicum) is a biopharmaceutical company that focuses on the development of immuno-oncology therapies for the treatment of solid tumors. The company’s lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell …
  • Ittehad Chemicals Ltd (ICL):企業の財務・戦略的SWOT分析
    Ittehad Chemicals Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Tryton Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Tryton Medical Inc (Tryton Medical) is a medical device company that develops novel stent systems for the treatment of bifurcation lesions. The company provides tryton side branch coronary artery stent, which is designed to treat, protect and secure coronary bifurcations. Its tryton side bra …
  • Damac Real Estate Development Ltd:企業の戦略・SWOT・財務分析
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Qiagen Marseille SA-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • Benitec Biopharma Ltd (BLT):医療機器:M&Aディール及び事業提携情報
    Summary Benitec Biopharma Ltd (Benitec) is a clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. It develops ddRNAi based th …
  • Uptake Medical Corp-医療機器分野:企業M&A・提携分析
    Summary Uptake Medical Corp (Uptake Med) is a healthcare technology company that develops medical technologies for the treatment of emphysema and lung cancer. The company develops intervapor therapy system, a bronchoscopic procedure in which heated water vapor is delivered to emphysematous lung tiss …
  • Sempra Energy (SRE):石油・ガス:M&Aディール及び事業提携情報
    Summary Sempra Energy (Sempra) is an energy-services holding company. Through its subsidiaries, the company invests in, develops, and operates energy infrastructure. It carries out utility operations, development of energy infrastructure and related services in countries including the US, Mexico, Ar …
  • TechnipFMC Plc.:企業の戦略・SWOT・財務分析
    TechnipFMC Plc. - Strategy, SWOT and Corporate Finance Report Summary TechnipFMC Plc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sagent Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • The E. W. Scripps Company:戦略・SWOT・企業財務分析
    The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report Summary The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Capita plc:企業の戦略・SWOT・財務分析
    Capita plc - Strategy, SWOT and Corporate Finance Report Summary Capita plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • TauRx Pharmaceuticals Ltd:医療機器:M&Aディール及び事業提携情報
    Summary TauRx Pharmaceuticals Ltd (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. Its pipeline products include LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal demen …
  • IVERIC bio Inc (ISEE):企業の財務・戦略的SWOT分析
    Summary IVERIC bio Inc (IVERIC bio) formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt di …
  • ProSiebenSat.1 Media AG (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media AG (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Flowserve Corporation:企業の戦略・SWOT・財務分析
    Flowserve Corporation - Strategy, SWOT and Corporate Finance Report Summary Flowserve Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Absorption Systems LP-製薬・医療分野:企業M&A・提携分析
    Summary Absorption Systems LP (Absorption Systems) is a pre-clinical contract research organization that develops and implements research tools. The organization carries out preclinical testing of drugs, biologics, and medical devices. It develops and implements research tools to predict human outco …
  • Ultradent Products Inc:企業の戦略的SWOT分析
    Ultradent Products Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • United Therapeutics Corp (UTHR):医療機器:M&Aディール及び事業提携情報
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆